Prima Biomed (ASX:PRR) today announced it had created a new research and development position to support its commercialisation abilities. [ + ]

Baby boomers will reap the benefits of a new medical research institute opened today at Concord Hospital, in western Sydney. [ + ]

The fate of Amrad Corporation's beleaguered board could fall in the lap of Victorian Treasurer and Innovation Minister John Brumby. [ + ]

Stringent guidelines and incomplete regulatory guidelines at home are forcing Australian and New Zealand biotechs offshore to test their novel diabetes treatments. But they are discovering that not everyone wants them. [ + ]

Melbourne company Cytopia has teamed with the Ludwig Institute for Cancer Research in Melbourne, the Queensland Institute of Medical Research (QIMR), and New York's Sloan-Kettering Institute for Cancer Research to develop new lead drug compounds for treatment of metastatic cancers based on the Eph receptor protein. [ + ]

Sydney start-up BioSignal has appointed a CEO, Swedish entrepreneur Michael Oredsson. [ + ]

Drug development and delivery company Norwood Abbey (ASX: NAL) is seeking partners to further progress its prototype microneedle. [ + ]

The Office of the Gene Technology Regulator (OGTR) has approved three new licenses to conduct field trials of genetically modified (GM) cotton. [ + ]

Bresagen (ASX: BGN) has been granted a 10-year head start on the development of its anti-leukaemia drug E21R. [ + ]

Brisbane-based company Agenix has successfully manufactured 1.4g of its clot-binding humanised antibody under good laboratory practice (GLP) conditions in preparation for pre-clinical testing of its Thromboview blood clot imaging system, the company said. [ + ]

It might not have been quite as exhilarating as his former life as a fighter pilot, but Iatia managing director Philippe Cussinet said the float of his company today was pretty exciting nonetheless. [ + ]

Prestigious scientific journal Nature has been forced to back away from its support of a controversial study claiming that transgenic DNA sequences from GM corn contaminated native maize in Mexico. [ + ]

Tests of an Australian cancer drug intended to block angiogenesis have progressed with the announcement of a third patient commencing treatment under the phase II study. [ + ]

Australian scientists and ethicists have expressed dismay and disbelief at reports a woman is eight weeks pregnant with the world's first human clone. [ + ]

G2 Therapies, a recent spin-off company from the Garvan Institute of Medical Research, will be launching into clinical trials of monoclonal targets to treat inflammatory diseases and cancer after raising $3.3 million in a first-round venture capital funding. [ + ]